Literature DB >> 12416449

Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy.

Barbara Schmidt1, Hauke Walter, Nina Zeitler, Klaus Korn.   

Abstract

The technical quality of genotypic and phenotypic drug resistance testing has considerably improved, and therefore the major challenge now lies in the interpretation of drug resistance. This is due to several facts: (i) in times of combination therapy, the effect of drug resistance-associated mutations cannot be considered independently, (ii) many additive and subtractive interactions between mutations exist, and resistant strains may exhibit varying degrees of cross-resistance, (iii) the phenotype cannot adequately determine slight, but clinically relevant, differences for those drugs with a narrow range of resistance, and (iv) pharmacokinetic interactions may shift relevant levels of drug resistance. Genotypic drug resistance interpretation systems are designed to solve these problems. Rule-based systems incorporate current knowledge about correlations between genotype, phenotype and clinical response. Database-driven systems use the information provided by paired geno- and phenotypic data, applying database matching search or bioinformatic approaches. For detailed comparison, 11 interpretation systems were selected which present a comprehensive system for most of the available drugs, can easily be accessed via the Internet and are regularly updated. The systems were characterized for the source data, access, input, output, and availability of clinical studies. For further comparison, existing clinical databases should be merged into one large database to allow competition between the systems. This may also solve the burning problem of clinically relevant cut-offs. Head-to-head comparisons of interpretation systems require large prospective randomized trials in which only the interpretation system is different between groups, before a consensus can be achieved for the best antiretroviral therapy of the individual patient.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416449

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  5 in total

1.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

2.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

3.  Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Authors:  Haili Zhang; Yan Zhou; Cecily Alcock; Tara Kiefer; Daphne Monie; Janet Siliciano; Quan Li; Paul Pham; Joseph Cofrancesco; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.

Authors:  Klaus Korn; Heide Reil; Hauke Walter; Barbara Schmidt
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

5.  Search algorithms as a framework for the optimization of drug combinations.

Authors:  Diego Calzolari; Stefania Bruschi; Laurence Coquin; Jennifer Schofield; Jacob D Feala; John C Reed; Andrew D McCulloch; Giovanni Paternostro
Journal:  PLoS Comput Biol       Date:  2008-12-26       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.